Impact of molecular subtype on 1325 early-stage breast cancer patients homogeneously treated with hypofractionated radiotherapy without boost: Should the indications for radiotherapy be more personalized?

Impact of molecular subtype on 1325 early-stage breast cancer patients homogeneously treated with hypofractionated radiotherapy without boost: Should the indications for radiotherapy be more personalized?

Aim: We report molecular subtype impact on 1325 early breast cancer (BCa) patients treated with whole breast hypofractionated (WBH) adjuvant forward-planned intensity modulated radiotherapy (F-IMRT) without boost. Methods and materials: From 02/2009-05/2017 1325 patients with pTis-pT3, pNx-N1aM0 BCa...

Full description

Bibliographic Details
Main Authors: Andrei Fodor, Chiara Brombin, Paola Mangili, Fulvio Borroni, Marcella Pasetti, Roberta Tummineri, Flavia Zerbetto, Barbara Longobardi, Lucia Perna, Italo Dell’Oca, Chiara L. Deantoni, Aniko M. Deli, Anna Chiara, Sara Broggi, Roberta Castriconi, Pier Giorgio Esposito, Najla Slim, Paolo Passoni, Simone Baroni, Stefano L. Villa, Paola M.V. Rancoita, Claudio Fiorino, Antonella Del Vecchio, Giampaolo Bianchini, Oreste D. Gentilini, Mariaclelia S. Di Serio, N.G. Di Muzio
Format: Article
Language:English
Published: Elsevier 2021-02-01
Series:Breast
Subjects:
Early stage breast cancer
Breast cancer conservative treatment
Hypofractionated whole breast radiotherapy
Tumor bed boost
Breast cancer molecular subtypes
Online Access:http://www.sciencedirect.com/science/article/pii/S0960977620302332

Internet

http://www.sciencedirect.com/science/article/pii/S0960977620302332

Similar Items